News

MASLD: Who should be treated and how to find them

A study shows that metabolic bariatric surgery improves metabolic control and substantially reduces insulin requirements in people with type 1 diabetes.

In a joint session at the 33rd European Congress on Obesity in Istanbul, EASO and EASD discussed metabolic health across the lifespan.

A recent review compares potential benefits and current barriers.

Seeds of success for young researchers

Preparing clinicians for the future of type 1 diabetes care

Exogenous ketones are gaining attention as a non-pharmacological, metabolic strategy in type 2 diabetes.

Diabetes education, CGM beyond T1D management, C-peptide levels

Overweight and obesity in T1D, IDF-ATTD joint symposium, presidential takeaways and announcements

Hot from the oven, CGM in T2D, apps in T2D

A European Diabetes Forum working group presents 14 recommendations to guide the use of AI in diabetes care.

A recent study found that children with a family history of type 2 diabetes show slower progression of type 1 diabetes.

As people with T1D live longer, age-related conditions such as dementia are becoming increasingly important.

Why normal glucose regulation should be the therapeutic goal rather than weight loss

The impact of diabetes on cardiovascular health remains one of the most urgent clinical challenges, influencing outcomes for millions worldwide.

Beta cell protection in new-onset type 1 diabetes, sleep and glycaemic control, EASD Global Impact Prize

SURPASS-CVOT primary results, technology in pregnancy, how to run a lab

New clinical guideline on diabetes distress, challenges to precision medicine in type 2 diabetes, ketone monitoring & minimum safety for CGM

Precision medicine approaches for monogenic diabetes, CGM in India and in exercise, and the emerging consensus on T1D screening

How large is the benefit of combining the GLP-1 and amylin mechanisms of action, and what are the implications for clinical practice?

Phase II trial shows that higher doses of up to 16 mg of the GLP-1 receptor agonist (RA) semaglutide improve glycaemia and induce weight loss at the cost of reduced tolerability.